The pharmaceutical industry is invested in ensuring that patients are represented in the form of patient-reported outcomes in clinical trials. However, many sources of real-world evidence used to support clinical trial evidence do not capture patient data adequately.

This can lead to barriers at stakeholder gatekeeper levels that may prevent the successful development and adoption of medicines, meaning that patient access to medications may be delayed or prevented, especially for those with rare diseases.